ImageneBio (IMA) Q3 2025 earnings summary

Executive summary

• Completed a reverse recapitalization merger with Ikena Oncology and a $75 million PIPE/private placement, resulting in a new public entity focused on immunology, autoimmune, and inflammatory diseases, with IMG-007 as the sole clinical-stage asset and a cash position of $142.6 million as of September 30, 2025.

• Initiated a Phase 2b clinical trial for IMG-007 in atopic dermatitis, with topline data expected in 2027.

• Divested all non-OX40 business assets prior to the merger, streamlining the pipeline to a single lead candidate.

• Strengthened leadership with new CEO, CSO, CTO, and independent director appointments.

• Advanced IMG-007, a non-depleting anti-OX40 monoclonal antibody, in clinical trials for atopic dermatitis and alopecia areata.

Financial highlights

• Net loss was $24.8 million for Q3 2025 and $38.4 million for the nine months ended September 30, 2025, compared to $3.2 million and $31.8 million for the same periods in 2024.

• Research and development expenses were $15.6 million for Q3 2025, up from $3.9 million in Q3 2024, primarily due to increased stock-based compensation and clinical program costs.

• General and administrative expenses rose to $11.0 million in Q3 2025 from $1.7 million in Q3 2024, driven by higher stock-based compensation and professional services.

• Cash, cash equivalents, and marketable securities totaled $142.6 million as of September 30, 2025, up from $12.1 million at December 31, 2024, due to the merger and financing.

• No revenue from product sales; $0.8 million in license revenue recognized in the nine months ended September 30, 2025.

Outlook and guidance

• Current cash position expected to fund operations for at least 12 months from the reporting date.

• Substantial additional funding will be required to advance IMG-007 through clinical development and potential commercialization.

• Topline data from the ongoing Phase 2b trial for IMG-007 in atopic dermatitis anticipated in 2027.

• Protocol amendment planned to optimize study design, dosing regimens, and patient experience.